12:00 AM
Feb 13, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Status

GSK2251052: Suspended Phase IIb enrollment

Anacor said partner GlaxoSmithKline suspended enrollment in all trials of GSK2251052 following a "microbiological finding in a small number of patients" in a Phase IIb trial to treat complicated urinary tract infections (cUTI). Anacor is working with GSK to investigate the finding, which the biotech said...

Read the full 209 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >